Fiche centre
Houston Methodist Hospital
Houston — United States
Essais liés17clinical trials
VilleHoustonlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04288726
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| imlifidase | SEP | Phase 3 | NCT04935177 | ConfIdeS — Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx | COMPLETED |
| BrioVAD System | Insuffisance cardiaque | Non applicable | NCT06310031 | INNOVATE — Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | ACTIVE_NOT_RECRUITING |
| Vasopressor | Maladie coronarienne | À vérifier | NCT04682483 | CSWG — Cardiogenic Shock Working Group Registry | RECRUITING |
| Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections | Sclérose latérale amyotrophique | Phase 2 | NCT04055623 | Tregs in ALS — T-regulatory Cells in ALS | COMPLETED |
| anito-cel | Myasthénie | Phase 1 | NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | RECRUITING |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| CD30.CAR-EBVST cells | Cancer | Phase 1 | NCT04288726 | Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel | Lupus | Phase 2 | NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | ACTIVE_NOT_RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | RECRUITING |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| YTB323 | Myasthénie | Phase 1/2 | NCT06704269 | Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Remibrutinib (Blinded) | Myasthénie | Phase 3 | NCT06744920 | RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Standard lymphodepletion regimen | Myasthénie | Phase 2/3 | NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | RECRUITING |
| CABA-201 | Myasthénie | Phase 1/2 | NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | RECRUITING |